Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raxone treatment for dominant optic atrophy due to OPA1 mutation
2019-001493-28Phase 2Completed
- Sponsor
- Medical University of Graz
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idebenone in dominant optic atrophy (DOA) and hereditary optic atrophy, sponsored by Medical University of Graz. Primary endpoint: Primary: Best recovery or least deterioration of visual acuity. Started Sep 2020; status: completed.
02
Drugs
idebenone
03
Conditions
dominant optic atrophy (DOA)hereditary optic atrophy
Beyond the preview
Go deeper on 2019-001493-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001493-28.